Replies to post #253483 on Biotech Values

[DewDiligence]

PFE's CSO said on yesterday's CC that he expects CDC to eventually settle on a 3-year re-vaccination schedule for RSV vaccines.

[DewDiligence]

More_on GSK’s dropping 24-valent pneumococcal vaccine—(from FierceBiotech):

https://www.fiercebiotech.com/biotech/gsk-axes-vaccine-21b-deal-switching-preclinical-successor-over-increased-competition

A spokesperson for GSK said “increased competition” drove the decision.

[DewDiligence]

I am not sure if PFE broke down adult vs maternal sales in their call.

They didn’t.